Pathology informatics selected abstracts
April 2026—Technical considerations during validation of Genius digital diagnostic system; Applicability of accreditation requirements to machine learning-based methods in molecular oncology testing
Webinars and Sponsored Roundtables — Register Now
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
2026 Issues
Q&A column
April 2026
Q. Do regulatory agencies still support sodium citrate platelet counts? What is the CAP’s standing? Read answer.
Newsbytes
April 2026—PathGroup, a clinical laboratory, partnered with Labgnostic to automate proficiency testing order entry and result delivery. LabgnosticPT, an application from Labgnostic, automates the PT process, integrating with laboratory information systems for seamless order and result transmission. This automation significantly reduces administrative time, allowing PathGroup staff to focus more on patient-centered work.
Put It on the Board
April 2026—Vitestro raised $70 million in Series B financing to advance its Aletta robotic phlebotomy device. The funding will support product development, manufacturing, clinical expansion, and commercial readiness for the Aletta, which uses imaging, robotics, and AI for blood collection.
Alzheimer’s blood tests poised to lead
March 2026—Blood-based biomarkers for Alzheimer’s disease, including the FDA-approved Lumipulse G pTau 217/β-Amyloid 1-42 and Elecsys pTau181 tests, are revolutionizing diagnosis and treatment. These less invasive tests offer earlier detection, improved accessibility, and potential for broader patient reach.
In MS diagnosis, the case for κ-FLC index
March 2026—An international panel of experts recommended including the determination of intrathecal kappa free light chain (κ-FLC) synthesis in the next revision of MS diagnostic criteria. The κ-FLC index, easily determined by nephelometry and turbidimetry, is a fast, cost-effective, and quantitative biomarker with high diagnostic value for MS. It also predicts future inflammatory disease activity and disability progression, making it a valuable prognostic tool.
Easing, clarifying of personnel requirements: ’25 accreditation checklists
March 2026—The Centers for Medicare and Medicaid Services announced changes to personnel requirements in response to feedback on the CLIA final rule.
For newer sepsis diagnostics, what the studies show
March 2026—Newer sepsis diagnostics, including monocyte distribution width, Intellisep, and MeMed BV, show promise in clinical studies but have limitations.
Lab leaders on outreach growth and competition
March 2026—Laboratory leaders from various health systems discussed strategies to navigate competition and ensure growth.
Point-of-care HCV RNA testing: at what cost?
March 2026—A University of Washington study analyzed HCV testing costs across its system from 2017 to 2024, focusing on the public county hospital ED where one-third of diagnoses occur.